Recruitment of glioma patients for phase I, II, and III trials using the CTLA-4 inhibitor ipilimumab (a mAb) in combination with a PD-1 inhibitor is ongoing (NCT04323046, NCT04396860, NCT04003649, NCT03233152, NCT04145115). Here, CTLA4 is linked to glioma.